Overall, the immunoliposome-based targeted delivery of the Cas9gRNA-hIL30 complex, which selectively inhibits tumor IL30 expression, has antiangiogenic and antiproliferative effects in both PC models and has antimetastatic efficacy in DU145 tumor model, without evidence of hematological or organ toxicity. Here, IL27 is linked to neoplasm.